Evidence map›Paper›PMID 24859879›Full record

ArticleHaematologica2014

Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Arnaud Jaccard, Raymond L Comenzo, Parameswaran Hari, Philip N Hawkins, Murielle Roussel, Pierre Morel, Margaret Macro, Jean-Luc Pellegrin, Estibaliz Lazaro, Dania Mohty and 7 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 129 citations in OpenAlex.

  1. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 4 countries.

Arnaud JaccardNational Amyloidosis Center and Hematology Unit, CHU Limoges, France arnaud.jaccard@chu-limoges.fr.
Raymond L ComenzoTufts Medical Center, Boston, MA, USA.
Parameswaran HariMedical College of Wisconsin, Milwaukee, WI, USA.
Philip N HawkinsCentre for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK.
Murielle RousselHematology Unit, CHU Toulouse, France.
Pierre MorelHematology Unit, CH Lens, France.
Margaret MacroHematology Unit, CHU Caen, France.
Jean-Luc PellegrinInternal Medicine Units, CHU Bordeaux, France.
Estibaliz LazaroInternal Medicine Units, CHU Bordeaux, France.
Dania MohtyNational Amyloidosis Center and Cardiology Unit, CHU Limoges, France.
Patrick MercieInternal Medicine Units, CHU Bordeaux, France.
Olivier DecauxInternal Medicine Unit, CHU Rennes, France.
Julian GillmoreCentre for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK.
David LavergneNational Amyloidosis Center and Hematology Unit, CHU Limoges, France.
Frank BridouxNephrology Unit, CHU Poitiers, France.
Ashutosh D WechalekarCentre for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK.
Christopher P VennerCentre for Amyloidosis and Acute Phase Proteins, University College London Medical School, UK Cross Cancer Institute, University of Alberta, Edmonton, Canada.
University College London · GBCentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier de Lens · FRCentre Hospitalier Universitaire de Caen · FRCentre Hospitalier Universitaire de Limoges · FRCentre Hospitalier Universitaire de Poitiers · FRCentre Hospitalier Universitaire de Rennes · FRMedical College of Wisconsin · USTufts Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bortezomib is an active agent in AL amyloidosis and responses to this drug in combination with cyclophosphamide and dexamethasone are both rapid and deep. Here we present an international, multicenter series of 60 patients with Mayo Clinic stage III cardiac amyloidosis to assess the impact of this regimen in improving outcomes in this poor-risk group. The median follow-up for the entire cohort is 11.8 months. The overall response rate was 68%. In a landmark analysis, examining patients who survived more than 3 months, the overall response rate was 86%. A cardiac response was seen in 32% of patients. The estimated 1-year survival rate for the whole cohort was 57% and 24 patients (40%) died while on therapy. Although unable to save the poorest risk patients, the combination of bortezomib, cyclophosphamide and dexamethasone can achieve a high number of hematologic and cardiac responses, likely improving overall survival and justifying a prospective trial.

Indexed as

AdultAgedAged, 80 and overAmyloidosisBoronic AcidsBortezomibCardiomyopathiesCyclophosphamideDexamethasoneDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImmunoglobulin Light-chain AmyloidosisImmunoglobulin Light ChainsMaleBoronic AcidsBortezomibCyclophosphamideDexamethasoneImmunoglobulin Light ChainsProtein AggregatesPyrazines

Identifiers

PMID24859879
PMCPMC4562537
OpenAlexW2003181078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.